HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $23

Benzinga Newsdesk www.benzinga.com Positive 79.1%

Neg 0% Neu 0% Pos 79.1%

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price target from $17 to $23.